Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics.

ABSTRACT:

Purpose

Pharmacogenomic biomarkers are increasingly listed on medication labels and authoritative guidelines but pharmacogenomic-guided prescribing is not yet common. Our objective was to assess the potential for incorporating knowledge of patients' genomic characteristics into prescribing practices.

Methods

We performed a retrospective analysis of claims data for 2,096,971 beneficiaries with pharmacy coverage from a national, commercial health insurance plan between January 2017 and December 2019. Children between 0 and 17 years comprised 21% of the cohort. Adults were age 18 to 64. Medications with actionable pharmacogenomic biomarkers (MAPBs) were identified using public information from the US Food and Drug Administration (FDA), Clinical Pharmacogenomics Implementation C

SUBMITTER: Liu D 

PROVIDER: S-EPMC9067543 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature